天舒胶囊辅助氟桂利嗪治疗前庭性偏头痛的效果及对患者血清5-HT、NO和MMP-9水平的影响

Effect of Tianshu Capsules Adjuvant Flunarizine in the Treatment of Vestibular Migraine and Its Influence on Serum 5-HT,NO and MMP-9 Levels of Patients

目的:探讨天舒胶囊辅助氟桂利嗪治疗前庭性偏头痛(VM)的效果及对患者血清5-羟色胺(5-HT)、一氧化氮(NO)和基质金属蛋白酶-9(MMP-9)水平的影响。方法:选取2020年1月-2022年1月锦州医科大学附属第一医院神经内科诊治的92例VM患者,按照随机数字表法将其分为两组,每组46例。对照组采用氟桂利嗪治疗,观察组在对照组的基础上加用天舒胶囊。比较两组疗效、视觉模拟评分法(VAS)评分、头痛发作频率、发作持续时间、头痛影响测试评分(HIT-6)、血清5-HT、NO、MMP-9水平和不良反应发生情况。结果:观察组总改善率为89.13%,高于对照组的71.74%(P<0.05)。治疗1、2、3个月后,观察组VAS评分均低于对照组(P<0.05)。治疗后,观察组发作持续时间短于对照组,头痛发作频率、HIT-6评分均低于对照组(P<0.05)。治疗后,观察组血清5-HT水平高于对照组,而NO、MMP-9水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:天舒胶囊辅助氟桂利嗪治疗VM能提高疗效,减少头痛发作频率,缩短发作持续时间,减轻头痛影响程度,降低血清5-HT、NO、MMP-9水平,且未增加不良反应,安全可靠。

Objective: To investigate the effect of Tianshu Capsules adjuvant Flunarizine in the treatment of vestibular migraine(VM) and its influence on serum serotonin(5-HT), nitric oxide(NO) and matrix metalloproteinase-9(MMP-9) levels of patients. Method: A total of 92 VM patients admitted to the Department of Neurology, the First Affiliated Hospital of Jinzhou Medical University from January 2020 to January 2022 were selected, they were divided into two groups according to the random number table method, with 46 cases in each group. The control group was treated with Flunarizine, and the observation group was treated with Tianshu Capsules on the basis of the control group. The efficacy, visual analogue scale(VAS) scores, frequency of headache attacks,duration of attacks, headache impact test score(HIT-6), serum 5-HT, NO, MMP-9 levels and adverse reactions were compared between the two groups. Result: The overall improvement rate in the observation group was 89.13%, which was higher than 71.74% in the control group(P<0.05). After 1, 2 and 3 months of treatment, VAS scores in the observation group were lower than those in the control group(P<0.05). After treatment, the seizure duration in the observation group was shorter than in the control group, headache attack frequency and HIT-6score in the observation group were lower than those in the control group(P<0.05). After treatment, the serum 5-HT level in the observation group was higher than that in the control group, while the NO and MMP-9 levels in the observation group were lower than those in the control group(P<0.05). There was no significant difference in the adverse reaction rate between the two groups(P>0.05). Conclusion: Tianshu Capsules adjuvant Flunarizine in the treatment of VM can improve the efficacy, reduce the frequency and duration of headache attacks, reduce the degree of headache, and reduce the levels of serum 5-HT, NO and MMP-9 without increasing adverse reactions,which is safe and reliable.